These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 37827694)

  • 21. Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus.
    Nakai T; Fukui S; Kidoguchi G; Ikeda Y; Kitada A; Nomura A; Tamaki H; Kishimoto M; Okada M
    Clin Rheumatol; 2022 Dec; 41(12):3735-3745. PubMed ID: 35939162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [What is new in the treatment of Systemic Lupus Erythematosus?].
    Skácelová M
    Vnitr Lek; 2022; 68(5):273-278. PubMed ID: 36283816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.
    Bertsias GK; Tektonidou M; Amoura Z; Aringer M; Bajema I; Berden JH; Boletis J; Cervera R; Dörner T; Doria A; Ferrario F; Floege J; Houssiau FA; Ioannidis JP; Isenberg DA; Kallenberg CG; Lightstone L; Marks SD; Martini A; Moroni G; Neumann I; Praga M; Schneider M; Starra A; Tesar V; Vasconcelos C; van Vollenhoven RF; Zakharova H; Haubitz M; Gordon C; Jayne D; Boumpas DT;
    Ann Rheum Dis; 2012 Nov; 71(11):1771-82. PubMed ID: 22851469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pragmatic approaches to therapy for systemic lupus erythematosus.
    Xiong W; Lahita RG
    Nat Rev Rheumatol; 2014 Feb; 10(2):97-107. PubMed ID: 24166241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
    Mok CC
    Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus.
    Athanassiou P; Athanassiou L
    Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.
    ; Silver R; Craigo S; Porter F; Osmundson SS; Kuller JA; Norton ME
    Am J Obstet Gynecol; 2023 Mar; 228(3):B41-B60. PubMed ID: 36084704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis.
    Wozniacka A; Salamon M; Lesiak A; McCauliffe DP; Sysa-Jedrzejowska A
    Clin Rheumatol; 2007 Jul; 26(7):1176-9. PubMed ID: 16645776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
    van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
    Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.
    Aringer M; Burkhardt H; Burmester GR; Fischer-Betz R; Fleck M; Graninger W; Hiepe F; Jacobi AM; Kötter I; Lakomek HJ; Lorenz HM; Manger B; Schett G; Schmidt RE; Schneider M; Schulze-Koops H; Smolen JS; Specker C; Stoll T; Strangfeld A; Tony HP; Villiger PM; Voll R; Witte T; Dörner T
    Lupus; 2012 Apr; 21(4):386-401. PubMed ID: 22072024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs.
    Ruiz-Irastorza G; Bertsias G
    Rheumatology (Oxford); 2020 Dec; 59(Suppl5):v69-v81. PubMed ID: 33280011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.
    Danve A; Perry L; Deodhar A
    Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
    Davis LS; Reimold AM
    Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i100-i113. PubMed ID: 28375452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response.
    Balevic SJ; Niu J; Chen J; Green D; McMahon A; Hornik CP; Schanberg LE; Glaser R; Gonzalez D; Burckart GJ
    J Clin Pharmacol; 2023 Jan; 63(1):105-118. PubMed ID: 35968821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcineurin inhibitors in systemic lupus erythematosus.
    Mok CC
    Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):429-438. PubMed ID: 29224682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic lupus erythematosus and risk of infection.
    Barber MRW; Clarke AE
    Expert Rev Clin Immunol; 2020 May; 16(5):527-538. PubMed ID: 32478627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing the use of existing therapies in lupus.
    Croyle L; Morand EF
    Int J Rheum Dis; 2015 Feb; 18(2):129-37. PubMed ID: 25884457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
    Drosos GC; Vedder D; Houben E; Boekel L; Atzeni F; Badreh S; Boumpas DT; Brodin N; Bruce IN; González-Gay MÁ; Jacobsen S; Kerekes G; Marchiori F; Mukhtyar C; Ramos-Casals M; Sattar N; Schreiber K; Sciascia S; Svenungsson E; Szekanecz Z; Tausche AK; Tyndall A; van Halm V; Voskuyl A; Macfarlane GJ; Ward MM; Nurmohamed MT; Tektonidou MG
    Ann Rheum Dis; 2022 Jun; 81(6):768-779. PubMed ID: 35110331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
    Hellmich B; Sanchez-Alamo B; Schirmer JH; Berti A; Blockmans D; Cid MC; Holle JU; Hollinger N; Karadag O; Kronbichler A; Little MA; Luqmani RA; Mahr A; Merkel PA; Mohammad AJ; Monti S; Mukhtyar CB; Musial J; Price-Kuehne F; Segelmark M; Teng YKO; Terrier B; Tomasson G; Vaglio A; Vassilopoulos D; Verhoeven P; Jayne D
    Ann Rheum Dis; 2024 Jan; 83(1):30-47. PubMed ID: 36927642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.